AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 131 min read$CYTK

Blum Robert I sold $472K of CYTK

Blum Robert I (President & CEO) sold 7,500 shares of CYTOKINETICS INC (CYTK) at $62.88 ($0.47M total) on 2026-10-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Blum Robert I
Published Oct 13, 2026, 8:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 8:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CYTK
Bearish
medium confidence
Mentioned
$CYTK
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CYTKBearishLow
01

Why it matters

The disclosed sale adds new information about insider sentiment, which can affect short‑term price action.

02

Market read

New insider sale provides fresh data for traders; likely modest downside pressure.

03

What to watch

Potential pre‑arranged 10b5‑1 plan reduces negative signal strength.

Relevance 3/10Novelty 3/10Timing: post‑market filing

Background

Form 4 filings disclose insider transactions; a sale by the CEO is noteworthy for traders.

Company-level read

Ticker impact

$CYTKBearishMedium confidence
Context

President & CEO Robert Blum sold 7,500 shares for $471,600 on 2026-10-12 via a Form 4 filing.

Expected impact

likely downward pressure as the market prices in the insider sell

Evidence & confidence

A C‑suite insider sold a sizable block at $62.88 per share; such sales often trigger short‑term selling pressure.

Market effects

Sector

Minimal; biotech sector may see slight sentiment drag from insider activity.

Regional

None

Global

Low

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to company fundamentals.

Key entities

  • person
    Robert Blum

    President & CEO of Cytokinetics Inc.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CYTK insider trading history →

Related articles

OCT 13
$CYTKHigh

Cytokinetics Highlights Exercise Capacity, Responder Data For Aficamten In NHCM At HFSA 2026

Cytokinetics (CYTK) presented data from the ACACIA-HCM trial at the HFSA 2026 meeting, showing aficamten improved exercise performance and clinical outcomes in non-obstructive HCM patients. The drug demonstrated significant benefits in exercise capacity, symptom relief, and safety, with 53% of patients showing improvements across multiple domains. CYTK reported a Q2 2026 net loss of $198.8M and $25.3M in aficamten revenue, with cash reserves of $1.7B.

rttnews.com2 min
OCT 12
$CYTKMed

Cytokinetics presents additional aficamten data from trial

Cytokinetics (CYTK) presented additional data from its ACACIA-HCM trial at the Heart Failure Society of America Annual Scientific Meeting. Aficamten showed statistically significant improvements in exercise performance and clinical response in patients with non-obstructive hypertrophic cardiomyopathy. The company plans to submit a supplemental New Drug Application to the FDA this quarter for this indication.

uk.investing.com1 min
OCT 12
$CYTKMed

Serious heart failure events affected 4.7% taking aficamten, versus 1.2% on placebo.

Cytokinetics (CYTK) presented additional data from the ACACIA-HCM trial at the HFSA Annual Scientific Meeting. The study showed aficamten improved exercise performance and safety in non-obstructive HCM patients. Serious heart failure events occurred in 4.7% of aficamten patients vs. 1.2% on placebo. The company plans to submit a supplemental New Drug Application to the FDA this quarter.

stocktitan.net4 min